New clinical study shows fewer adverse events with Bactiguard’s central venous catheter compared to a standard central venous catheter

A recently published clinical study* conducted at the Karolinska University Hospital in Sweden shows that Bactiguard’s infection prevention central venous catheter – BIP CVC had significantly fewer adverse events compared to a standard uncoated CVC. The study also shows that Bactiguard’s noble metal alloy does not expose patients or the environment to any risks in blood applications.

“This study confirms that the Bactiguard coating is durable and safe for patients also in blood applications and it shows promising results when it comes to reducing device related complications such as sepsis and thrombosis”, says Gunilla Björling, PhD and researcher at the Swedish Red Cross University College and Karolinska Institute, who is the first author of the publication.

The study was conducted on patients undergoing major abdominal surgery. 34 patients were randomized in two groups, 12 patients received standard CVCs and 22 patients received Bactiguard CVCs. When comparing the outcome, no adverse events were reported in the Bactiguard group, while five adverse events (of which 3 catheter-related) were reported in the control group.

The study also analyzed the amount of noble metals in patient blood and on the catheters after use of BIP CVC. The concentration in blood was far below permitted daily exposure (PDE) for chronic use and far below those required to develop microbial resistance. The noble metal levels on the catheters after use showed that the coating is durable in blood during entire usage time. The study is published in Journal of Biomedical Materials Research and is available on PubMed.


For further information, please contact:
Dorota Johansson, Clinical and Research Director, mobile: +46 706 54 31 71
About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com